Avacta GroupAVCTF 13 Pretax Margin % is -33,777.63% as of Dec. 2025. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 947 Biotechnology companies, Avacta Group ranks worse than 96.3% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Avacta Group's Pre-Tax Income for the
six
months ended in Dec. 2025 was $-25.67 Mil. Avacta Group's Revenue for the
six
months ended in Dec. 2025 was $0.08 Mil. Therefore, Avacta Group's pretax margin for the quarter that ended in Dec. 2025 was -33,777.63%.
The historical rank and industry rank for Avacta Group's Pretax Margin % or its related term are showing as below:
AVCTF'
s Pretax Margin % Range Over the Past 10 Years
Min: -32604.42 Med: -655.55 Max: -257.04
Current: -31900.89
AVCTF's Pretax Margin % is ranked worse than 96.3% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs AVCTF: -31900.89
Avacta Group (OTCPK:AVCTF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Avacta Group Pretax Margin % Related Terms
Avacta Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Avacta Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Avacta Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Avacta Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Pretax Margin % of -33,777.63% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #912 out of 947 companies in the Biotechnology industry, placing it in the top 96.3%.
Is Avacta Group's Pretax Margin % too high?
Avacta Group's current Pretax Margin % is -33,777.63%. Based on the distribution chart, Avacta Group ranks #912 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #912 out of 947 companies for Pretax Margin %. This places Avacta Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Avacta Group and its competitors. Avacta Group's current Pretax Margin % is -33,777.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current Pretax Margin % is -33,777.63%. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Pretax Margin % is -33,777.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Pretax Margin %: -33,777.63%
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
